Methods: In a prospective observational study, we recruited consecutive adults hospitalized with confirmed pandemic 2009 H1N1 infection during a 16-week period. Nasopharyngeal aspirate and non-respiratory samples (blood, stool and urine) were collected at presentation, and serial nasopharyngeal flocked swabs (NPFS) and tracheal aspirates (TA) were collected after initiating oseltamivir treatment for quantitative viral RNA assay, using real-time reverse transcriptase-PCR. Serial plasma samples were collected for cytokine/chemokine assay using cytometric bead array. Patients with severe pneumonia (lung infiltrates and hypoxaemia) were compared to those with milder illnesses. Results: A total of 66 patients were studied (mean age 43 ±20 years); 28 (42%) developed severe pneumonia, of whom 10 (15%) required intubation. Severe pneumonia was associated with older age, dyspnoea, delayed presentation >2 days from onset, extrapulmonary virus detection 
Introduction similar to seasonal influenza, some progress to develop lower respiratory complications and pneumonia, leading to hospitalizations and deaths [2, 3] . By March 2010, there were an estimated 265,000 excess hospitalizations caused by 2009 H1N1 infection in the US alone [4] ; worldwide, over 17,700 laboratory confirmed deaths were reported to the World Health Organization [1] . Among adults hospitalized for pandemic 2009 H1N1 virus-associated pneumonia, 9-31% have required intensive care unit (ICU) care, and 14-46% of them died [5] [6] [7] [8] [9] [10] . Rapid progression to respiratory failure might occur. Delayed presentation, increased age, pregnancy and presence of underlying medical conditions have been associated with critical illnesses and poor outcomes [8, 11, 12] .
Antiviral treatment data of influenza is largely based on studies involving ambulatory patients suffering from mild seasonal influenza; few data exist for hospitalized patients with severe infection, including that caused by the pandemic 2009 H1N1 virus [2, 6, [13] [14] [15] . In this study, we report the virological response with neuraminidase inhibitor treatment and associated inflammatory cytokine profiles in a cohort of adult patients hospitalized for 2009 H1N1 virus infection. Such information might have important implications for patient management, and provides data for the planning of future clinical trials.
Methods

Study population
A prospective, observational study was conducted among adult patients hospitalized with laboratory confirmed pandemic 2009 influenza A(H1N1) infection. Consecutive patients were recruited from the medical departments of two hospitals during a 16-week period (from 1 June to 30 September 2009; first wave of infection in Hong Kong SAR) if they fulfilled these criteria: aged >16 years, presented with acute febrile respiratory illnesses, with or without pneumonia, confirmed 2009 H1N1 virus infection by real-time reverse transcriptase (RT)-PCR and provided written informed consent for study. Patients who were pregnant and those who refused or were unable to provide consent were excluded ( Table 1 ). The two participating hospitals are acute general public hospitals operating under the Hospital Authority of Hong Kong [15, 16] . Ethical approval for the study was obtained from the Institutional Review Boards of the Hospital Authority of Hong Kong and The Chinese University of Hong Kong (Hong Kong SAR, China).
Case-finding and management of influenza infection
Hospital admission procedures of adult influenza patients have been described in our previous studies [15] [16] [17] [18] . In brief, patients presenting with acute febrile respiratory illnesses would be considered for hospitalization if they develop potentially serious medical conditions/complications, exacerbation of underlying illnesses or severe symptoms that were unmanageable at home [15, 16] . Regardless of the perceived aetiology, nasopharyngeal aspirate (NPA) was collected at presentation from all such patients to test for 2009 H1N1 virus using a specific real-time RT-PCR assay (see section on Clinical data, collection of specimens and definitions) [15, 17, 19] . Consecutive patients were identified and recruited by the laboratory and clinical research teams on a daily basis, once the diagnosis was confirmed and before treatment began [15] . For patients with diagnosis already established by RT-PCR on nasal/throat swabs before hospital admission, NPA was omitted. Sputum samples were routinely collected for bacterial culture. Blood cultures were performed if there were signs of sepsis.
Antiviral treatment for pandemic 2009 A(H1N1) infection had not been standardized and evolved during the study period [13] . According to local recommendations, antiviral treatment would be considered for all pandemic H1N1-infected patients who require hospitalization, but no restrictions were made on the choice of antivirals or the regimen used [20] . Standard dose of oseltamivir at 75 mg twice daily was used in most patients; however, clinicians were allowed to increase the dose (for example, 150 mg twice daily) and/or extend the duration of therapy to beyond 5 days if deemed necessary.
Clinical data, collection of specimens and definitions
Clinical information was collected systematically by designated research staff using a standardized data collection form, which included information on demographics, presenting features, clinical course, treatments and outcomes [15] [16] [17] . Nasopharyngeal flocked swabs (NPFS) were collected once per day from each patient for serial quantitative viral RNA monitoring for 1 week or until discharge, whichever came sooner. In some cases, specimen collection was continued because of ongoing illness. Stool, urine and blood ('non-respiratory') samples were collected once after admission for viral RNA detection [21] . In patients who were mechanically ventilated, a tracheal aspirate (TA) was collected once per day for serial viral monitoring during the period of intubation. For cytokine studies, peripheral blood (EDTA) samples were collected on alternate days for 2 weeks or until discharge [18] . Serial chest radiographs were performed to monitor progress of pneumonia to assist patient management. In severe pneumonia cases that required ICU care, chest radiography was performed daily for close monitoring.
'Severe pneumonia' was defined as radiographic pneumonia (including consolidation or ground-glass infiltrates) and hypoxaemia, with requirement of supplemental oxygen therapy to maintain oxygen saturation (SpO 2 )>95%. Patients were classified as having 'mild pneumonia' if their pneumonia did not cause hypoxaemia (SpO 2 >95% on room air), or 'no pneumonia' if they presented with symptoms/complications other than pneumonia (Table 1) .
Virological studies
For diagnosis, NPAs collected at presentation were subjected to viral antigen-detection for influenza A and B, respiratory syncytial virus and parainfluenza viruses using an immunofluorescence assay [15, 17] , and a realtime RT-PCR assay specific for the haemagglutinin gene of the pandemic 2009 influenza A(H1N1) virus [19] . For enrolled patients, real-time RT-PCR assay targeting the matrix (M) gene was performed for viral RNA Results of comparisons between patients with severe pneumonia and those with no (n=30) or mild (n=8) pneumonia. During the study period, 23 pregnant women (all non-severe cases) and 37 patients who refused or were unable to provide consent (31 were non-severe cases) were excluded from the analysis based on our criteria.
b Chronic medical conditions, including chronic heart, liver, renal, pulmonary (chronic obstructive pulmonary disease [COPD], asthma and fibrosis), neurological, and neoplastic diseases, diabetes mellitus and use of immunosuppressants [15] [16] [17] [18] . Obesity was the only risk factor identified in two patients. Other complications than pneumonia noted in this cohort included (by episodes): acute exacerbation of COPD/asthma (n=8), cardiovascular (n=3) and neurological (n=3) manifestations, and syncope (n=3). All 66 patients received oseltamivir therapy. Among them, 22 (33%) received a dosage of 150 mg twice daily, and the rest received 75 mg twice daily; 4/22 had dosages transiently increased beyond 150 mg twice daily, but later reduced. In 5 cases, concomitant zanamivir (intravenous or inhalation route) was given for a brief period. High-dose/'pulse' corticosteroids were not used for treating viral pneumonia in this cohort. Nine patients received systemic corticosteroids in conventional doses for exacerbation of COPD or asthma. Bacterial coinfection was documented at presentation in 6 (9%) cases (S. pneumoniae n=3, S. aureus n=1, M. catarrhalis n=1 and Klebsiella spc n=1); another 6 cases developed nosocomial infections with resistant gramnegative pathogens. None had coinfection with other respiratory viruses. Management in intensive care units included intubation and mechanical ventilation (n=10) and extracorporeal membrane oxygenation (n=1). IQR, interquartile range; NS, not statistically significant based on P-value of >0.05; WBC, white blood cell.
quantitation [17] [18] [19] . Virus isolation was performed by the National Influenza Centre (Centre for Health Protection, Hong Kong SAR, China) under Biosafety Level III containment during the study period [20] ; the serial NPFS, TA and non-respiratory tract (blood, urine and stool) samples were also tested by real-time RT-PCR for quantitative viral RNA assay [17] [18] [19] . Virus isolation had not been performed for these specimens.
Viral RNA was extracted from the clinical specimens (NPA, TA, NPFS, stool, urine and blood samples) using the PureLink™ Viral RNA/DNA kit (Invitrogen, Carlsbad, CA, USA). A one-step real-time RT-PCR was designed to target the M gene of influenza A viruses as previously described [17, 19] . Viral RNA concentration was quantified by running the real-time PCR reaction in the presence of standards with a known number of copies of M gene cloned in the plasmid pCR2.1-TOPO (Invitrogen). The lower detection limit of the assay was 0.75 RNA copies/ml of specimen.
Genotyping resistance testing (H275Y mutation, which confers resistance to oseltamivir) was also performed by neuraminidase gene sequencing using previously described methods [22] . Testing was done on the last PCR-positive samples collected from 24 patients with pneumonia who had either required intensive care, shown prolonged viral shedding >5 days post-treatment or reversion from PCR-negativity to PCR-positivity [22] .
Cytokine/chemokine assays
Methods used to study cytokine/chemokine responses in influenza patients have been described previously [18] . 
Radiological assessment
All frontal chest radiographs of patients were reviewed by an experienced, independent radiologist blinded to clinical and laboratory information to assess for the presence, appearance, distribution and extent (percentage area of lung parenchyma, and the number of zones involved) of lung parenchymal abnormality. Details of the methods have been described (Additional file 1) [23] .
Statistical analyses
Patients with 'severe pneumonia' were compared with patients with milder illnesses, that is, those with 'no' or 'mild' pneumonia. Descriptive statistics were reported as mean ±sd or median (interquartile range [IQR] ) based on data distribution. The Student's t-test, Mann-Whitney U, and χ 2 tests were used for univariate comparisons whenever appropriate. Influenza viral RNA concentrations (expressed in copies/ml of specimen) were log-transformed for statistical analyses. Variables with P-values <0.1 in the univariate analyses were entered into backward stepwise logistic regression models to determine independent factors associated with severe pneumonia. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each explanatory variable. Multiple linear regression models (backward) were used to identify independent factors affecting viral concentration [17] . The regression coefficient (b), se and 95% CI were reported for the explanatory variables. Spearman's rank correlation coefficient (rho) was used to assess for correlation between cytokine/chemokine concentration and the extent of pneumonia, or with viral RNA concentration [18] . In all analyses, a P-value of <0.05 was considered to indicate statistical significance. All probabilities were two-tailed. Statistical analysis was performed using PASW Statistics software version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Description of cohort
Altogether, 66 patients were studied; all were ethnic Chinese. Radiographic pneumonia was evident at presentation in 36 (54.5%) patients, and 28 (42%) were classified as severe pneumonia because of hypoxaemia. Of these, 13 (46%) required admission to ICUs for support, and 10 (36%) were intubated and mechanically ventilated. The demographics, clinical presentations and outcomes of patients with severe pneumonia were compared to those with milder illnesses (Table 1) Radiologically, multizonal involvement was evident at presentation in 54% of pneumonia cases; in 37% there was further progression, with peak extent reached within a median (IQR) of 3 (2-6) days after hospital admission. Detailed radiographic descriptions of H1N1 influenza pneumonia are provided in Additional file 1.
All 66 patients received oseltamivir; the dosage of 150 mg twice daily was used in 22 (33%) severe cases. The median duration of oseltamivir treatment was 10 days (IQR 6-13) in severe pneumonia, and 5 days in all milder cases. No patient had received high-dose corticosteroids for viral pneumonia (Table 1) . Two (3%) patients with severe pneumonia died after 2 weeks of intensive care. The median duration of oxygen therapy required and length of stay among survivors of severe pneumonia was 6 days (IQR 4-16) and 11 days (IQR 7-24) respectively. For the milder illness group, the median length of stay was 4 days (IQR 3-5).
Virological findings
Findings at presentation
The initial diagnosis of pandemic 2009 A(H1N1) virus infection was confirmed in 48 patients by NPA and in 18 patients by nasal/throat swabs. The overall culture positivity rate was 80% in these samples. The mean ±sd viral RNA concentration in NPA was 5.7 ±1.5 log 10 copies/ml. Higher NPA viral RNA concentration was associated with positive immunofluorescence assay results for influenza A (6.5 ±1.3 versus 4.9 ±1.2 log 10 copies/ml; P<0.01) and with positive viral cultures (5.8 ±1.3 versus 4.6 ±1.8 log 10 copies/ml; P<0.05). The average viral RNA concentration at presentation (pretreatment and within the first 4 days of illness) was 1.3 logs higher in patients with severe pneumonia than those with milder illnesses (mean 6.5 ±1.2 versus 5.2 ±1.7 log 10 copies/ ml; P=0.024). After adjusting for confounders including time elapsed from onset, age and comorbidities, we found that severe pneumonia was significantly associated with higher viral RNA concentration at presentation (multiple linear regression: b=0.94, ±se 0.39, 95% CI 0.15-1.74; P=0.02; Figure 1 ). Viral RNA was detected in 13% of peripheral blood, 13% of urine and 28% of stool samples. Detailed clinical descriptions of the 20 patients who had positive virus detection in one or more sampling sites are provided in Additional file 2. Most had severe pneumonia (65%) and/or major comorbidities (45%). Extrapulmonary virus detection at any site tended to associate with severe pneumonia (adjusted OR 3.99, 95% CI 0.89-17.86; P=0.07), after adjustment for comorbidities, age and gender; it also tended to associate with a higher viral RNA concentration in the initial NPA (mean ±sd 6.38 ±1.69 versus 5.01 ±1.95 log 10 copies/ml; P=0.06). (Figure 2) . In some cases of severe pneumonia, a rising trend of viral RNA concentration was observed despite 4-5 days of antiviral treatment ( Figure 2 ). Viral RNA levels in TA were studied in 10 intubated patients. In general, the corresponding viral RNA concentration was substantially higher in TA from the lower tract, and viral clearance was much slower, than in the NPFS from the upper tract (Figure 3 ). The median (IQR) duration of viral RNA positivity after start of oseltamivir was 11.0 days (7.8-14.3) in TA. In most cases, even after 5 days of treatment, the viral RNA concentrations remained high at 4-7 log 10 copies/ml. Despite viral RNA becoming undetectable in NPFS, it continued to be detected at high levels in TA after treatment commenced in all but one intubated patient.
Hospital course
In three patients with severe pneumonia, viral rebound was detected (Figure 2 ). After stopping oseltamivir (given for 5-7 days), there was reversion from RNA negativity to RNA positivity in NPFS at an interval of 1, 3 and 6 days, respectively. Viral rebound in the lower respiratory tract/TA was noted to follow that of the upper tract/NPFS in one case (patient 2; Figure 3 ). The longest duration of viral detection documented in TA was 24 days after oseltamivir initiation; the patient had received corticosteroids for chronic obstructive pulmonary disease exacerbation and oseltamivir treatment for 14 days. The H275Y mutation in NA was not found in any of these patients or other intubated cases, or in those with detectable virus after 5 days of treatment.
Plasma cytokine/chemokine responses
The plasma cytokine/chemokine responses were studied in 24 patients with severe pneumonia and 29 patients with milder illnesses. The first blood samples were taken at a median of 4 days (IQR 3-7) from illness onset. At presentation, plasma IL-6, CCL2 (MCP-1) and CXCL-8 (IL-8) concentrations were found to be 17-, 5-and 3-fold higher in patients with severe pneumonia than those with milder illnesses (Table 2 and Additional file 3). Rises in CXCL-10 (IP-10), sTNFR-1 and IL-10 levels were also observed. After adjusting for confounders, including time-to-presentation, age and comorbidities, increased IL-6 concentration was independently associated with the development of severe pneumonia (adjusted OR 1.1, 95% CI 1.0-1.2 per-unit increase; P=0.004). Elevated CCL2, CXCL-8 and sTNFR-1 concentrations were similarly found to be associated with severe pneumonia in multivariate analyses. Cytokine/chemokine profiles of patients during the hospital course are described in Figure 4 . Concentrations of plasma cytokine/chemokine was found to correlate significantly with the extent of pneumonia by percentage on chest radiographs, both at presentation (Spearman's rho for IL-6, CXCL-8, CCL2 and sTNFR-1 was 0.61, 0.64, 0.70 and 0.56, respectively; all P<0.01) and at their peak extent of infiltration (Spearman's rho for IL-6, CXCL-8, CCL2 and sTNFR-1 was 0.63, 0.58, 0.70 and 0.54, respectively; all P<0.01). Calculations based on number of radiographic zones involved showed similar results (NL et al., data not shown).
The initial plasma concentrations of these cytokines/ chemokines also tended to correlate with the viral RNA concentrations in the lower respiratory tract/TA measured on the corresponding day in the ten patients who had required intensive care and intubation (Spearman's rho for IL-6, CXCL-8, CCL2 and sTNFR-1 was 0. 
Discussion
Our findings are consistent with earlier reports indicating that severe pandemic 2009 influenza A(H1N1) virus pneumonia is associated with older age, presence of comorbidities, lower respiratory tract symptoms, delayed presentation or antiviral treatment >2 days from onset, and high morbidity [2, 3, 7, 8, 12] . Our study adds that adults hospitalized for severe pneumonia have high viral loads despite their late presentation, and that viral clearance is slow despite oseltamivir treatment. High viral loads might persist in the lower respiratory tract even with apparent clearance in the upper tract, and viral rebound might occur with premature termination of treatment. Our findings indicate the need for more prolonged antiviral therapy in patients with serious pandemic H1N1-associated pneumonia. We also found evidence for sustained proinflammatory responses in those with higher lower respiratory viral loads and severe pneumonia. These results suggest that more potent antiviral regimens and perhaps use of immunomodulatory agents need to be explored in future studies.
In uncomplicated seasonal influenza, viral replication in the upper respiratory tract usually peaks with symptom onset and starts to subside after 48 h [14, 17] . With the novel 2009 H1N1 virus, however, spontaneous clearance can be slower because of lack of pre-existing or cross-immunity [2, 24, 25] ; viral shedding has been shown to persist for almost 1 week in the upper tract in uncomplicated infections [26] [27] [28] [29] . Because the virus has the ability to bind to both a2,6-and a2,3-linked cellular receptors, and to replicate efficiently in the lung, it could cause diffuse pneumonitis [2, [30] [31] [32] [33] . In such cases, particularly in patients who had major comorbidities and impaired host defence [17, 34] , the virus burden can become very high. This might explain why high viral load was seen in pneumonia patients despite their late presentation, even at ≥4 days from onset [2, 35, 36] . Therefore, it seems unlikely that ambulatory treatment data and paradigms in seasonal influenza (for example, onset <48 h) can be directly applied to patients hospitalized for severe 2009 H1N1 pneumonia [2, 6, 7, 13, 14, 29, 35] . Data regarding antiviral treatment response in 2009 H1N1 infections have been largely limited to virological assessments in the upper respiratory tract [29, 36, 37] . In this study, we observed slow virological response to oseltamivir treatment in severe 2009 H1N1 pneumonia. The median duration of viral RNA detection in the upper respiratory tract was 6 days after antiviral initiation versus only 2 days in milder illness. In the lower respiratory tract, it was even longer at 11 days (75th percentile was 14 days), although we did not detect oseltamivir resistance (H275Y mutation) in any of the cases. It is unlikely that the detection of nonviable, residual virus can explain our findings because the level of RNA concentration was still quite high (in the range of 4-7 log 10 copies/ml in the TA) and in some cases with a rising trend, even after 4-5 days of treatment. Reversion from RNA negativity to RNA positivity (viral rebound) after stopping treatment was also documented (Figures 2 and 3 ). These data, together with evidence of ongoing inflammation (indicated by hypercytokinaemia) [35] and clinical illness (indicated by oxygen desaturation and radiological progression) beyond 5 days in severe pneumonia, strongly argue for an extended antiviral treatment course. We support the recent recommendation to consider a 10-day course in such patients, followed by careful clinical and virological monitoring, especially in immunocompromised hosts [2, 13] . It should also be pointed out that viral kinetic profiles in upper and lower respiratory tracts are different. Virus might appear to be cleared from the upper respiratory tract despite a persistently high level of viral replication in the lungs [38, 39] . Therefore, it is prudent to include the use of lower respiratory tract specimens (such as tracheal or bronchoscopic aspirates) for the diagnosis and monitoring of severe H1N1 pneumonia, if available [2, 38] . Furthermore, the prolonged detection of virus in seriously ill patients could have infection control implications, particularly the duration of isolation precautions [28, 40] .
Finally, we found up-regulated plasma cytokine responses during the course of severe 2009 H1N1 pneumonia, driven by high-level sustained viral replication [18, 35, 36, 41] . The plasma levels of IL-6, CXCL-8 (IL-8) and CCL2 (MCP-1) in the severe pneumonia cases were noted to be higher than those with milder illness, as well as those reported in hospitalized adults with seasonal influenza (Table 2 ), but were less intense than those reported in H5N1 disease [2, 18, 32, 35, 36, 41] . Importantly, we have shown that the concentration of these cytokines/chemokines correlated well with the extent and progression of pneumonia, which might support a direct pathogenic role The cytokine results in hospitalized seasonal influenza patients have been published [18] , and are described here for reference. The same assays were used for both the seasonal and pandemic influenza cohorts. The plasma reference ranges are established from >100 healthy adults. The assay sensitivities of IL-1b, IL-6, IL-10, IL-12p70, TNF-a, IL-8, MIG, IP-10, MCP-1, RANTES, IFN-g, soluble TNF receptor-1 (sTNFR1) and IL-18 were 2.5, 3.3, 3.7, 1.9, 7.2, 0.2, 2.5, 2.8, 2.7, 1.0, 7.1, 0.8 and 9.2 pg/ml, respectively. Coefficients of variation were all <10% [18] . Most patients had undetectable plasma levels for TNF-a, IFN-g, IL-12p70, and IL-1b, or presented at very low levels; these values are therefore not reported.
b Significantly higher plasma levels in cases with severe pneumonia (n=24) when compared with those with milder illnesses (n=29); Mann-Whitney U, P<0.05. IQR, interquartile range; NA, not available. [18, 35, 41] . IL-6 has been identified as the key proinflammatory cytokine linked to fever and influenza symptom formation, and the development of severe illness and complications [18, 33, 36] . CXCL-8 is a neutrophil chemoattractant, which is implicated in the pathogenesis of acute respiratory distress syndrome [18] . CCL2 activates and recruits monocytes and granulocytes in influenza pneumonia [18, 33] . Whether early control of viral replication can attenuate these proinflammatory cytokine responses, or whether a particular immunomodulatory agent has a role in clinical management, will require further study; however, it should be noted that corticosteroid administration has been associated with prolonged viral shedding and increased mortality in severe influenza infection [17] , and is generally not recommended [2, 13] . The strengths of our study included simultaneously monitoring of upper and lower respiratory tract virological profiles [38] , a prospective and systematic approach to collecting serial samples based on established frameworks [17, 18] , and being multicentred. Our study was limited by the fact that virus isolation was performed only for the initial NPA specimens, whereas for subsequent NPFS or TA specimens, only quantitative viral RNA assay was performed; however, we believe it is unlikely that detection of residual virus RNA can account for our findings based on factors already described (high viral concentrations, the rising levels or rebound and ongoing illness) [27] [28] [29] 36] . In addition, culture has its limitations in detecting virus shedding and might produce false-negatives [2, 17, 28, 29, 34] . Notably, in one hospital-based study involving patients with milder illnesses and without pneumonia, the durations of positive PCR and culture after oseltamivir initiation were found to be comparable (mean ±sd 5 ±0.8 and 4 ±1.8 days, respectively; n=6 NPFS) [29] .
Our findings of slow viral clearance with treatment call for further studies on the management of severe 2009 H1N1 pneumonia. In addition to duration of therapy, the dosages of antivirals required to achieve optimal therapeutic response [2, 13] , use of intravenous therapies [2, 42, 43] , combination regimes [42] , and monitoring and treatment of drug-resistant viruses [2, 44] in such patients warrant attention. Strategies to prevent nosocomial transmission, including duration of isolation precaution, also warrant future study [28, 40] .
In conclusion, there is a high level of viral replication in severe 2009 H1N1 pneumonia. Viral clearance is slow with antiviral treatment, particularly in the lower respiratory tract. Our data support the use of a more sustained course of antiviral therapy, and call for further studies on management of this emerging disease.
